ClinicalTrials.Gov Participation Is Up From 2002 Rate Of 35%, FDA Report Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency calls participation in ClinicalTrials.gov "mixed," despite recent increase in use.
You may also be interested in...
FDA ClinicalTrials.gov Report Will Show Growing Rate Of Study Listings
The forthcoming report also will show increased disclosure of company sponsors and drug names in trial descriptions. FDA has added language to IND acknowledgement letters to promote compliance with listing requirements.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?